截至到2025年3月11日，由Sam S Yoon作为负责人的已经被撤回包括在MOLECULAR CANCER RESEARCH，Cancer Research，CLINICAL CANCER RESEARCH 及Cell Death & ...

Figure 1: Domain architecture of the classic poly-ADP-ribose-polymerase PARP1 and the newly characterized mono-ADP-ribosyltransferase PARP10. Figure 2: Classification of the poly-ADP-ribose ...

Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Under the terms of the settlement, Allarity has consented, without admitting or denying the SEC’s findings, to the entry of an administrative cease-and-desist order. The settlement resolves the SEC’s ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness in patients with platinum-resistant or refractory ovarian cancer. These patients typically have ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of ... repair defects with response to treatment with PARP inhibitors marked the first successful application ...